Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-53408 placebo-controlled trial in adults with celiac disease undergoing gluten challenge
2024-517081-42-00Phase 2Authorised
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing TEV-53408 with Placebo comparator (2 arms). Primary endpoints: Change from baseline in villous atrophy, Treatment-emergent adverse events and 3 more. Planned start Aug 2025; status: authorised.
02
Drugs
TEV-53408
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2024-517081-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517081-42-00.